ABOS (Acumen Pharmaceuticals) Current Accrued Expense: $11.62 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABOS Acumen Pharmaceuticals Inc ABOS
34 GF Score
Price $2.12
! 3 Warning Signs
View Full Analysis

What is Acumen Pharmaceuticals Current Accrued Expense?

Acumen Pharmaceuticals ABOS -2.29% 34 Current Accrued Expense is $11.62 Mil as of Mar. 2026. GuruFocus rates ABOS with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Acumen Pharmaceuticals's Current Accrued Expense for the quarter that ended in Mar. 2026 was $11.62 Mil.

Acumen Pharmaceuticals's quarterly Current Accrued Expense increased from Sep. 2025 ($12.80 Mil) to Dec. 2025 ($16.29 Mil) but then declined from Dec. 2025 ($16.29 Mil) to Mar. 2026 ($11.62 Mil).

Acumen Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2023 ($6.82 Mil) to Dec. 2024 ($17.39 Mil) but then declined from Dec. 2024 ($17.39 Mil) to Dec. 2025 ($16.29 Mil).

Acumen Pharmaceuticals Current Accrued Expense Related Terms

Acumen Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Acumen Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acumen Pharmaceuticals Current Accrued Expense Chart

Acumen Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 2.75 3.93 6.82 17.39 16.29

Acumen Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.83 20.61 12.80 16.29 11.62
ABOS
34GF Score
Acumen Pharmaceuticals Inc ABOS
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acumen Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $11.62 Mil mean?
Acumen Pharmaceuticals (ABOS) has a Current Accrued Expense of $11.62 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Acumen Pharmaceuticals and its competitors.
Is Acumen Pharmaceuticals' Current Accrued Expense too high?
Acumen Pharmaceuticals' current Current Accrued Expense is $11.62 Mil. Overall, Acumen Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Acumen Pharmaceuticals' Current Accrued Expense compare to YDES and PYXS?
Acumen Pharmaceuticals' Current Accrued Expense of $11.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Acumen Pharmaceuticals and its competitors. Acumen Pharmaceuticals's current Current Accrued Expense is $11.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acumen Pharmaceuticals stock overvalued right now?
Acumen Pharmaceuticals (ABOS) has a current Current Accrued Expense of $11.62 Mil. The current Current Accrued Expense is $11.62 Mil. Acumen Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Acumen Pharmaceuticals (ABOS), the current Current Accrued Expense is $11.62 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acumen Pharmaceuticals Business Description

Address 1210-1220 Washington Street, Suite 210, Newton, MA, USA, 02465
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
34GF Score

Get the complete analysis for ABOS

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.12
Price